| Primary |
| Hypertension |
34.3% |
| Blood Pressure Systolic Increased |
25.7% |
| Pre-eclampsia |
11.4% |
| Brain Oedema |
5.7% |
| Premature Labour |
5.7% |
| Product Used For Unknown Indication |
5.7% |
| Blood Pressure Systolic Increased |
2.9% |
| Blood Pressure Management |
2.9% |
| Preterm Premature Rupture Of Membranes |
2.9% |
| Thrombosis Prophylaxis |
2.9% |
|
| Death |
30.0% |
| Renal Failure Acute |
26.7% |
| Pulmonary Oedema |
6.7% |
| Renal Injury |
6.7% |
| Staphylococcal Scalded Skin Syndrome |
6.7% |
| Drug-induced Liver Injury |
3.3% |
| Injection Site Swelling |
3.3% |
| Linear Iga Disease |
3.3% |
| Maternal Exposure During Pregnancy |
3.3% |
| Neonatal Hypotension |
3.3% |
| Premature Baby |
3.3% |
| Transposition Of The Great Vessels |
3.3% |
|
| Secondary |
| Product Used For Unknown Indication |
69.3% |
| Hypertension |
6.8% |
| Suicide Attempt |
6.8% |
| Pre-eclampsia |
4.0% |
| Fluid Replacement |
1.7% |
| Diuretic Therapy |
1.1% |
| Immunosuppressant Drug Therapy |
1.1% |
| Maternal Therapy To Enhance Foetal Lung Maturity |
1.1% |
| Neutropenic Sepsis |
1.1% |
| Pyrexia |
1.1% |
| Acute Lymphocytic Leukaemia |
0.6% |
| Brain Oedema |
0.6% |
| Candiduria |
0.6% |
| Constipation |
0.6% |
| Drug Use For Unknown Indication |
0.6% |
| Foetal Disorder |
0.6% |
| Hyperglycaemia |
0.6% |
| Hypertensive Nephropathy |
0.6% |
| Infection |
0.6% |
| Lupus Nephritis |
0.6% |
|
| Completed Suicide |
15.6% |
| Respiratory Arrest |
12.5% |
| Exposure Via Ingestion |
6.3% |
| Oliguria |
6.3% |
| Premature Baby |
6.3% |
| Retinopathy Hypertensive |
6.3% |
| Toxicity To Various Agents |
6.3% |
| Agranulocytosis |
3.1% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
3.1% |
| Exposure During Pregnancy |
3.1% |
| Infection |
3.1% |
| Linear Iga Disease |
3.1% |
| Maternal Exposure During Pregnancy |
3.1% |
| Multi-organ Failure |
3.1% |
| Overdose |
3.1% |
| Thrombocytopenic Purpura |
3.1% |
| Thrombophlebitis Superficial |
3.1% |
| Umbilical Cord Vascular Disorder |
3.1% |
| Venoocclusive Liver Disease |
3.1% |
| Vomiting |
3.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
35.7% |
| Drug Use For Unknown Indication |
14.2% |
| Hypertension |
13.9% |
| Pneumonia |
9.3% |
| Pain |
4.4% |
| Pathological Fracture |
4.2% |
| Prophylaxis |
3.7% |
| Acute Myeloid Leukaemia |
1.7% |
| Hiv Infection |
1.5% |
| Anaesthesia |
1.2% |
| Diabetes Mellitus |
1.2% |
| Epilepsy |
1.2% |
| Ill-defined Disorder |
1.2% |
| Renal Cell Carcinoma |
1.2% |
| Blood Pressure Abnormal |
1.0% |
| Cardiovascular Disorder |
1.0% |
| Oliguria |
1.0% |
| Pancreatic Carcinoma |
1.0% |
| Anticoagulant Therapy |
0.7% |
| Atrial Fibrillation |
0.7% |
|
| Stevens-johnson Syndrome |
12.0% |
| Aortic Dissection |
10.0% |
| Pancytopenia |
8.0% |
| Respiratory Failure |
8.0% |
| Incoherent |
6.0% |
| Multi-organ Failure |
6.0% |
| Toxic Epidermal Necrolysis |
6.0% |
| Weight Decreased |
6.0% |
| Hyponatraemia |
4.0% |
| Neonatal Respiratory Distress Syndrome |
4.0% |
| Pain |
4.0% |
| Placenta Praevia |
4.0% |
| Renal Failure Acute |
4.0% |
| Sepsis |
4.0% |
| Thrombocytopenia |
4.0% |
| Abdominal Pain |
2.0% |
| Autoimmune Haemolytic Anaemia |
2.0% |
| Blood Thyroid Stimulating Hormone Increased |
2.0% |
| Bradycardia |
2.0% |
| Cardiac Arrest |
2.0% |
|
| Interacting |
| Induction Of Anaesthesia |
31.6% |
| Hypertension |
21.1% |
| Tachycardia |
21.1% |
| Maintenance Of Anaesthesia |
10.5% |
| Sedation |
10.5% |
| Liver Transplant |
5.3% |
|
| Drug Interaction |
66.7% |
| Drug Level Increased |
33.3% |
|
